(Q46701464)

English

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

1 reference

based on heuristic

inferred from title

object named as

Adam J Mead

1

0 references

6

object named as

David C Linch

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

2

object named as

Rosemary E Gale

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

author name string

Panagiotis D Kottaridis

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

Satomi Matsuda

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

Asim Khwaja

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

language of work or name

0 references

publication date

12 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

141

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

454-460

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Flt3 mutations and leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Clinical implications of FLT3 mutations in pediatric AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Novel therapeutic agents in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Flt3-dependent transformation by inactivating c-Cbl mutations in AML

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07025.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2008.07025.X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18341639

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46701464&oldid=2127360035"